Skip to main content

PATIENT CASE STUDIES

ARE YOUR UNCONTROLLED CRSwNP
PATIENTS CANDIDATES FOR
DUPIXENT?1

ARE YOUR UNCONTROLLED CRSwNP
PATIENTS CANDIDATES FOR
DUPIXENT?1

Do you have CRSwNP patients like these?

Consider DUPIXENT for patients with uncontrolled CRSwNP who have any of the following signs of type 2 inflammation1-10:

Repeated SCS bursts and/or history of sinus surgery2,3

Loss of smell2,4-6

Nasal congestion2,4,5

Polyp recurrence7,8

History of diseases driven in part by type 2 inflammation5,9,10

UP TO 87%

of patients with CRSwNP have evidence of type 2 inflammation11

Explore Some of the Possible Patient Types Right for DUPIXENT

CRSwNP, chronic rhinosinusitis with nasal polyps; INCS, intranasal corticosteroids; NC, nasal congestion/obstruction; NPS, nasal polyp score; SCS, systemic corticosteroid; SNOT-22, 22-item Sino-Nasal Outcome Test; t2i, type 2 inflammation; UPSIT, University of Pennsylvania Smell Identification Test.

Frequently Asked Questions About CRSwNP

Patient Types

DUPIXENT is indicated as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).1

Some examples of CRSwNP patients who may be appropriate for DUPIXENT are1:

  • Patients who are uncontrolled despite use of SCS and previous sinus surgery
  • Patients who are surgery naive
  • Patients with a history of asthma
  • Patients with comorbid NSAID-ERD

NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease; SCS, systemic corticosteroids.

Up to 87% of patients with CRSwNP have evidence of type 2 inflammation.11 DUPIXENT helps address the underlying type 2 inflammation in CRSwNP by targeting two of the key drivers—IL-4 and IL-13 signaling.1,13,14,a

aThe mechanism of dupilumab action has not been definitively established.1

SINUS-24 and SINUS-52

DUPIXENT is appropriate for surgery-naive or -experienced patients and may provide rapid results at Day 3 for Loss of Smellb and Day 2 for nasal congestion,c sustained through Week 52.1,12,15,d-g Data in adults.1,12,15

bLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).12,16 Patient-reported outcome. Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.12,17

cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).12,16 Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.12

dLoS score at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).15

eNC score at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,15

fLoS score at Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1 Analysis was not multiplicity controlled. Results are descriptive.15

gNC score at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).1,15

Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1

Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1

CRSwNP, chronic rhinosinusitis with nasal polyps; INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.1